New research published in JAMA Network Open “raises doubt” about a major U.S. Centers for Medicare & Medicaid Services (CMS) justification for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third, the study’s
…
Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.
Lujan’s chief of staff
The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients. The independent nonprofit group evaluates prescription drugs and medical treatments’ cost effectiveness
…
UPDATE Friday, Jan. 28, 2022—This story was updated to include comments by Pharmaceutical Research and Manufacturers of America (PhRMA.)
340B hospitals “are losing significant resources” due to drug companies’ conditions on 340B pricing when covered entities use contract pharmacies, according
…
More than half (52%) of the $81 billion that U.S. pharmacies and health care providers collected in 2020 in reimbursement from payers for brand-name prescription drugs came through pharmacy and provider participation in the 340B program, up from 14% of
…
A new two-pager about the 340B program by drug industry consultant Berkeley Research Group (BRG) indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.
The infographic came to light Sunday. It includes
…
U.S. retail prescription drug spending hit $348.4 billion in 2020, constituting 8% of total health care expenditures, a new federal report shows.
The U.S. Centers for Medicare & Medicaid Services (CMS) yesterday published its annual national health care spending report
…
The ban on 340B pricing on orphan drugs for over 1,000 hospitals may give companies that make drugs used primarily for common diseases or conditions a strong financial incentive to get an orphan designation for those drugs, a federal watchdog
…
Drug distributor AmerisourceBergen’s business consulting unit Xcenda has written an issue brief for drug industry-led group AIR340B saying Congress and the executive branch should revise 340B eligibility standards to keep 340B “from being used solely as a profit center for
…
Makers of seven of 10 top drugs in the U.S. hiked those drugs’ prices substantially in 2020 with no new evidence of improved safety or effectiveness, led by AbbVie’s anti-inflammatory blockbuster Humira, an influential drug pricing watchdog group says.
The
…*Sign up for news summaries and alerts from 340B Report